A Randomized Six-Day Safety Study of an Antiretroviral Microbicide Candidate UC781, a Non-Nucleoside Reverse Transcriptase Inhibitor.
Goal: This study evaluated the effect of a single dose and 5 additional consecutive daily doses of vaginal gel containing the microbicide UC781, at concentrations of 0.1%, 0.25%, 1.0%, and 0%, on urogenital irritation. Study Design: Forty-eight healthy sexually abstinent women in Virginia, USA, were randomly assigned to 1 of 4 groups. Methods: Urogenital irritation was assessed by pelvic examination, colposcopy, and reports of genital symptoms at baseline and after 1 and 6 doses. Vaginal health was assessed by wet mount and systemic safety by laboratory evaluation after 1 and 6 doses, and UC781 levels were assessed at baseline and after 6 doses. Results: Some evidence of urogenital irritation was common in all treatment groups and was most often transient and mild. Colposcopic findings were infrequent in the placebo group (8%) and more common in the 3 treatment groups (24%-42%). Oedema, which may indicate underlying inflammation, was observed in the vaginal fornix of 2 women exposed to UC781. There was no apparent increase in vaginal infection or clinically significant changes in laboratory values. Two of 12 participants randomized to 1% UC781 gel had detectable plasma levels that were less than the lower level of quantification. Conclusions: UC781 was well tolerated in this initial dose-ranging safety study when used once daily for 6 days in sexually abstinent women. Five safety/pharmacokinetic studies of UC781 are currently underway in women and men, all utilizing UC781 concentrations less than 1%, with twice-daily dosing in some studies, and all involving careful monitoring of exposed epithelium.
Sexually Transmitted Diseases (2008) 35 (4) 414-419 [doi: 10.1097/OLQ.0b013e318162c4d8].